P-LLY Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about retatrutide as a potential treatment for adults with obesity or overweight and at least one weight-related comorbidity, potential efficacy and tolerability of retatrutide, and the timeline for future readouts, presentations, and other milestones relating to retatrutide and its clinical trials and reflects Lilly's current beliefs and expectations
Medication history: prior GLP-1, tirzepatide, insulin, or sulfonylurea use
Where semaglutide engages one incretin receptor and tirzepatide engages two, retatrutide is engineered as a single peptide designed to activate GLP-1 and GIP and to add glucagon-receptor agonism
$60 to $105 with insurance Key Specs Accepts insurance: Yes Weight loss program included: No GLP-1 brand names offered: Zepbound, Wegovy, Saxenda, Ozempic, Mounjaro, Victoza Type of GLP-1 available: Injectable Cancel any time: Yes Nurx specializes in care for women, and providing weight-management programs is just one of the companys many offerings
While tirzepatide is a gold-standard diabetes treatment right now, retatrutides multi-pathway profile suggests it could offer an equally powerful, if not uniquely specialized, alternative for severe insulin resistance and advanced metabolic syndrome once approved
It takes around 45 half-lives (about 2430 days) to clear
